Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)

The 16-week trial is an open-label cross-over trial which includes heamodialysis patients with T2D and T1D on insulin therapy. During one period, patients carry a non-blinded CGM. In the other period they follow standard procedures (the last two weeks with a blinded CGM). The patients and the dialysis staff can use the CGM measures to regulate insulin and food intake during the non-blinded weeks. The research group will collect the CGM-data during the trial.

Inclusion Criteria:≥ 18 yearsChronically ill heamodialysis patients (heamodialysis or heamodiafiltration - treatment)der modtager HD- eller hæmodiafiltrationsbehandling på dialyseafsnit,--Patients at dialysis wards in Aalborg and Hjørring, Aalborg University Hospital (center and home patients)T1D or T2D and in treatment with insulinBeing able to use CGM equipmentSigned consentExclusion Criteria:Pregnancy or breastfeeding,Terms that, in the opinion of the investigator or subinvestigators, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participatePatients undergoing peritoneal dialysis (PD) or heamofiltration dialysis (HF)Acute HD treatmentGestational diabetes